InsiderDB
Sign inStart free trial

Rep. Robert P. Bresnahan, Jr. bought Charles River Laboratories International (CRL)

Rep. Robert P. Bresnahan, Jr. (R-PA-8) · $15K–$50K · traded Apr 8, 2025

Transaction
Bought
Amount
$15K–$50K
Owner
Not stated
Traded
Apr 8, 2025
Disclosed
May 8, 2025
Days to disclose
30
Asset type
Stock
As filed
Charles River Laboratories International, Inc. Common Stock
Industry
Medical - Diagnostics & Research · Healthcare
Official filing ↗All of Bresnahan's tradesAll Congress trades in CRL

Other trades in this filing

All of Bresnahan's trades →

Recent Congress trades in CRL

Company context for CRL

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. CRLLobbying report·Lobbying disclosures

    CRL: third_quarter 2026 lobbying report

    Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.

    Public: Oct 20, 2026, 9:28 PM EDTOriginal source ↗
  2. CRLLobbying report·Lobbying disclosures

    CRL: second_quarter 2026 lobbying report

    Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.

    Public: Jul 20, 2026, 10:36 PM EDTOriginal source ↗

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.